Table 3 Characteristics of patients by age at the beginning of biologic treatment according to biologic compound, number of biologic drugs, and reasons for suspension
< 16 Years | ≥16 Years | p Value | |
|---|---|---|---|
Number of patients | 137 (29.2) | 332 (70.8) | |
Age at the beginning of biological treatment | 9.0 [4.2] | 30.2 [11.4] | < 0.001 |
Years of disease progression | 2.7 [3.1] | 19.5 [2.1] | < 0.001 |
Biologic compound | |||
Etanercept | 81 (59.1) | 123 (37.1) | < 0.001 |
Adalimumab | 31 (21.6) | 58 (17.5) | |
Infliximab | 9 (6.6) | 134 (40.4) | |
Tocilizumab | 8 (5.8) | 8 (2.4) | |
Abatacept | – | 5 (1.5) | |
Anakinra | 6 (4.4) | 2 (0.6) | |
Certolizumab | 2 (1.5) | – | |
Golimumab | – | 2 (0.6) | |
Reason for suspension | |||
Inefficacy | 26 (37.1) | 80 (37.4) | < 0.001 |
Remission | 18 (25.7) | 17 (7.9) | |
Adverse event | 20 (28.6) | 60 (28.0) | |
Loss of tracking | 4 (5.7) | 20 (9.4) | |
Pregnancy or gestational desire | – | 13 (6.1) | |
Other reasons | 2 (2.9) | 22 (10.3) | |
Unknown | – | 2 (0.9) | |
Number of biologic drugs | |||
1 drug | 83 (60.6) | 183 (55.1) | 0.244 |
> 1 drug | 54 (39.4) | 149 (44.9) | |
2 | 27 (19.7) | 67 (20.2) | |
3 | 13 (9.5) | 38 (11.5) | |
4 | 11 (8.0) | 12 (3.6) | |
5 or more | 3 (2.2) | 32 (9.6) | |